Market Place
Sourcing Support
ESMO: Lilly`s RET drug shrinks half of rare thyroid cancers
30 Sep 2019 //
FIERCE BIOTECH
Lilly`s RET drug shrinks more than half of rare thyroid cancers
29 Sep 2019 //
FIERCE BIOTECH
Shrinking 60% of lung cancers, Blueprint`s RET drug poised for 2020 filing
04 Jun 2019 //
FIERCE BIOTECH
NICE looks to toss Sanofi, Ipsen thyroid cancer drugs from CDF
24 Aug 2017 //
FIERCE PHARMA
NICE rejects thyroid cancer drugs
23 Aug 2017 //
PHARMA TIMES
AstraZeneca Completes Divestment Of Caprelsa To Genzyme
06 Oct 2015 //
NASDAQ
AstraZeneca tops Q2 estimates on strength of diabetes drugs and clot-buster Brilinta
30 Jul 2015 //
FIERCE PHARMA
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Caprelsa® (vandetanib) from AstraZeneca
27 Jul 2015 //
BUSINESS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.